This result signified that UBE2O expression enables distinction between benign and malignant prostate tumors, as immunohistochemical studies in prostate cancer display a substantial disparity of UBE2O staining cells between benign and malignant lesions. This evidence concerns the gene UBE2O and prostate carcinoma.